(NASDAQ: FTH) Faeth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Faeth Therapeutics's earnings in 2026 is -$184,458,000.On average, 8 Wall Street analysts forecast FTH's earnings for 2026 to be -$117,782,430, with the lowest FTH earnings forecast at -$211,744,602, and the highest FTH earnings forecast at -$23,404,122. On average, 8 Wall Street analysts forecast FTH's earnings for 2027 to be -$9,374,397, with the lowest FTH earnings forecast at -$18,227,316, and the highest FTH earnings forecast at -$3,057,613.
In 2028, FTH is forecast to generate -$9,112,450 in earnings, with the lowest earnings forecast at -$12,769,642 and the highest earnings forecast at -$4,494,831.